China, AstraZeneca
AstraZeneca, breast cancer
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.Cho0xxI9.js ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback